Indeed, the development of liraglutide for obesity using a 3-mg daily dosing regimen further illustrates that much greater tolerability to GLP-1 can be achieved using progressive stepwise titration regimens
Taking a GLP-1
Proper screening, dosing adjustments, and side-effect monitoring reduce risk and improve outcomes
Patients who maintain a healthy lifestyle experience faster weight loss
Only 13 states provided coverage as of January 2026, down from 16 states in 2025, likely reflecting the significant costs of coverage and recent state budget challenges and federal funding cuts
Disclosures: Alfred Barritt IV: Merck (Any division): Advisor, Madrigal: Consultant, Life Edit: Consultant, Boehringer Ingelheim: Consultant, Target-RWE: Consultant, Andrea Mospan: Nothing to Disclose, Breda Munoz: Nothing to Disclose, Rohit Loomba: Eli Lilly and Company: Consultant, Michael Fried: Nothing to Disclose, Brent Neuschwander-Tetri: Akero: Consultant, Aligos: Consultant, Arrowhead: Consultant, Corcept: Consultant, GSK: Consultant, Hepion: Consultant, HIstoIndex: Consultant, Madrigal: Consultant, Madrigal: Grant/Research Support, Merck: Consultant, Mirum: Consultant, Sagimet: Consultant, Senseion: Consultant, HepGene: Stock privately held company, HeptaBio: Stock privately held company, Philip Newsome: Novo Nordisk: Consultant, B Ingelheim: Consultant, Madrigal: Consultant, 89 Bio: Consultant, Sagimet: Consultant, Echosens: Speaking and Teaching, Eli Lilly: Speaking and Teaching, Zydus Therapeutics: Consultant, Abbott: Speaking and Teaching, Kenneth Cusi: Nothing to Disclose, Arun Sanyal: Genfit, Akarna, Tiziana, Durect, Inversago, Hemoshear, North: Stock - publicly traded company, Astra Zeneca ( 60K), Boston Pharmaceutical ( 50% OoF tiles were flagged as inadequate quality for reporting
